Regeneron/Sanofi's sarilumab heading for regulators for RA
This article was originally published in Scrip
Sanofi and Regeneron have reported topline data from three Phase III trials of their novel anti-inflammatory MAb sarilumab in rheumatoid arthritis that will support filings due in the fourth quarter.
You may also be interested in...
The leading PARP inhibitor gets a new tumor type added to its label after a narrow ODAC vote in favor less than a fortnight ago.
Andrew McConaghie and Alex Shimmings are joined by John Hawkins, biographer of biotech pioneer Henri Termeer, and Idea Pharma's Mike Rea to pick out their personal book highlights of 2019.
Concerns that written interventions might delay the expected EU approval of the novel ketamine-based antidepressant have come to naught.